Late Results of Mitral Valve Repair With Glutaraldehyde-Treated Autologous Pericardium

A Systematic Review of Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation for Rheumatic Mitral Regurgitation

“…In a series of 78 patients with rheumatic MV disease who underwent complex valve repair in which a combination of these techniques was used, the cumulative survival and freedom from significant recurrent MR and valve reoperation were 94%, 94%, and 83% at 8 years, respectively [26]. When an insufficient amount of native leaflet tissue remains after debridement or there are severely shortened and fibrotic rheumatic chordae tendinea, MV replacement should be considered because these factors are associated with a high risk of repair failure [7,27].…”

Long-Term Outcomes of Mitral Valve Repair for Active Endocarditis

“…9 Shomura and colleagues reported MV repair with glutaraldehyde-treated autologous pericardium and 5-year rates of freedom from reoperation of 94±3% decreasing to 10 years of 82±7% in their series. 25 Although using autologous pericardium in MV repair can avoid the use of prosthetic valves in patients with AE, there is a case report of a patient with a history of mitral and aortic valve repair with glutaraldehyde-treated autologous pericardium undergoing double valve replacement for mitral stenosis that developed because atrial fibrillation received permanent anticoagulation therapy with warfarin after surgery. Patients with sinus rhythm received anticoagulation for the first 3 months after surgery.…”

Invited Commentary

“…Shomura and associates [1] report their retrospective experience with 139 patients undergoing mitral valve repair with autologous glutaraldehyde-treated pericardium between March 1992 and November 2011 (average 14.5 patients per year for 9.5 years) followed for more than a 19-year period (mean follow-up 4.5 years).…”